Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

NCT00726544 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

100

Enrollment

INDUSTRY

Sponsor class

Stopped Enrollment into study was slower than expected.

Conditions

Thrombotic Microangiopathy
Thrombotic Thrombocytopenic Purpura

Interventions

DRUG: ARC 1779 Placebo
DRUG: ARC1779 Injection
DRUG: ARC1779 Injection
DRUG: ARC1779 Injection

Sponsor

Archemix Corp.